Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03273712 · ClinicalTrials.gov registry record · Phase 2
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
A Phase 2 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03273712 is a Phase 2 study that has completed, run by University of Iowa. The registered enrollment target is 39 participants.
The verdict
NCT03273712, a Phase 2 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
Interventions
- RADIATION 90Y-DOTA tyr3-Octreotide
- DIAGNOSTIC_TEST 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan
- DRUG Amino Acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03273712
The ClinicalTrials.gov registry entry for NCT03273712 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 90Y-DOTA tyr3-Octreotide is the first listed.
NCT03273712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03273712 about?
NCT03273712 is a clinical study titled "Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)". This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
What is the current status of trial NCT03273712?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2017-09-29. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT03273712?
The interventions under investigation include: 90Y-DOTA tyr3-Octreotide (RADIATION), 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan (DIAGNOSTIC_TEST), Amino Acids (DRUG).
Who is sponsoring clinical trial NCT03273712?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.